Voriconazole is a broad-spectrum triazole antifungal agent.
Indication: Used in the treatment of patients with progressive, possibly life-threatening fungal infections such as candidaemia in non-neutropenic patients, invasive candidiasis in skin, abdomen, kidney, bladder wall and wounds, invasive aspergillosis and infections caused by Scedosporium apiospermum and Fusarium spp in patients intolerant/refractory to other therapies.
Application: Administered by intravenous infusion.
Dosage form |
Lyophilized vials |
||
Strength |
200mg |
||
Compliance |
USP |
||
Manufacturing site |
CMO for Xellia Pharmaceuticals ApS |
||
Release site |
CMO for Xellia Pharmaceuticals ApS |
||
Site registered |
US FDA Other health authorities |
||
Batch size |
|
||
Regulatory documentation |
US dossier RoW* dossier |
||
Packaging sizes |
|
||
Shelf life |
| ||
Storage conditions |
| ||
* Rest of the World
